Suplatast tosilate

Research use only, not for human use.

A Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.

A Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production; suppresses IgE production, eosinophil infiltration and histamine release; exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.Allergy Approved(In Vitro):IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis.IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC).(In Vivo):Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum.

IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis.IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC).

Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum. Animal Model:Female BALB/c mice (6-8 weeks old) are immunized with ovalbuminDosage:100 mg/kg Administration:P.o. once a day for 21 days Result:Reduced the number of total cells and eosinophils.Almost completely inhibited the development of antigen-induced bronchial hyperresponsiveness (BHR).Decreased the levels of IL-4, IL-5 and IL-13.

IPD-1151T

Apoptosis

IL Receptor

Th2cytokine

Inflammation/Immunology

Allergy

94055-76-2

499.6406

C23H33NO7S2

>98% (HPLC)

DMSO: ≥ 33 mg/mL

CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1

Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, 4-methylbenzenesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years